PDE4A and systemic sclerosis: However, although in vivo results can provide information about the effects of PDE4 inhibition on pathological scar, the HOCl model is characterized by systemic inflammation producing fibrosis in other tissues such as kidney or lung, more relevant to SSc (Bagnato et al. 2013), which may be interpreted as a limitation of this study.